October 11, 2017

Kindara Now Accepting Investments In Equity Crowdfunding Round

Kindara has been qualified by the SEC to accept investments for Regulation A+ offering

BOULDER, Colo., Oct. 11, 2017 /PRNewswire/ -- Kindara, a female-focused company that provides women the interconnected tools, knowledge, and support to understand how their fertility works, announced today that they are now accepting investments for their Series A fundraise. Kindara has partnered with SeedInvest, a leading equity-based crowdfunding platform, to offer this investment opportunity to both accredited and non-accredited investors through a Regulation A+ offering. "With over 1.4 million downloads, our community has proven how passionate they are about Kindara," said Kindara CEO, Ira Hernowitz. "Almost half of new investments are going toward funding the development of exciting new technologies and product enhancements for the Kindara Community. New tools and resources are in the pipeline that will continue to keep Kindara positioned as the leader in the femtech fertility space, with many of these new technologies currently in late-stage development and ready for retail next quarter."

Since announcing the company's intentions to fundraise in late June, Kindara has unveiled four new points of potential profitability:

  • Kindara Premium - The trusted Kindara Fertility App, downloaded over 1.4 million times and being used more than twice a day on average with over 90,000 daily sessions, has been updated to include new features, including Kindara Premium; a subscription-based platform within the Kindara App that offers community members more data fields, customization and greater access to develop public and private community groups to continue to grow their support system.
  • New Kindara Wink - The Kindara Wink, which pairs specifically with the Kindara App and has garnered more than 1.7 million dollars in revenue for the brand, will have a next generation model Basal Body Temperature (BBT) thermometer in early 2018 with the same functionality at a lower price- which opens up retail and healthcare distribution channels. 
  • Kindara DNA - Kindara DNA, the first at-home DNA test designed specifically to sync with a trusted fertility app, will be released in early 2018 through a partnership with personal genomics company Helix.
  • Kindara Fertility Coaching - Through a partnership with SymptoPro's network of highly experienced and trained fertility education instructors, Kindara Fertility Coaching aims to take the guesswork out of Fertility Awareness Based Methods (FABMs) utilizing personalized one-on-one professional education and coaching for women looking to help make sense of their charts and further their understanding of FABMs.

With over 4 million new data points a month, Kindara can leverage fully anonymized and de-identified data to dive deeper into analytics to help more women meet their fertility goals. To this end, Kindara recently announced a collaboration with Ecole Polytechnique Fédérale de Lausanne (EPFL) Digital Epidemiology – Global Health Institute – Life Science Faculty out of Switzerland. The study aims at using de-identified and anonymized data to compare cycles, identify patterns and detect variations that could indicate medical conditions such as Polycystic Ovary Syndrome (PCOS).

"With so many exciting new opportunities and the proven passion of our existing and still growing community, we expect this investment round to fuel the growth that we are so excited about," said Hernowitz.

Kindara's current investment round will cap at $3,500,000, and minimum investments start at $1,000. To place an investment or learn about this investment opportunity please visit, https://www.seedinvest.com/kindara/series.a.

ABOUT KINDARAKindara is a female-focused company that provides women the interconnected tools, knowledge, and support to understand how their fertility works, take ownership of their reproductive health, and meet their fertility goals. Based in Boulder, Colorado, Kindara has been at the forefront of the Femtech revolution since its inception in 2011.

Kindara's cornerstone product, the Kindara Fertility App, has over 1.4 million downloads on iOS and Android, and has helped over 150,000 women around the world achieve pregnancy since its launch in 2012. The app pairs with Wink by Kindara, a Bluetooth- connected Basal Body Temperature (BBT) thermometer that helps seamlessly track fertility data with greater ease and accuracy. To further support women along their family planning journey Kindara recently announced a collaboration with Helix, a personal genomics company, and plans to release Kindara DNA, the first at-home DNA test designed specifically to sync with a trusted fertility app, in early 2018. For more information, please visit www.kindara.com.

Kindara Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Kindara Inc.: https://www.seedinvest.com/kindara/series.a.

This profile and accompanying offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company's actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.

Meet your fertility goals and better understand your body with the world's most powerful and useful fertility charting system.